Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard first-line treatment for patients with PD-L1 combined positive score (CPS) ≥5. ...
NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 23, 2025 /PRNewswire/ -- Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic...
GUANGZHOU, China, Jan. 23, 2025 /PRNewswire/ -- On the evening of January 16, 2025, the annual "China Top Employers" list was announced. Infinitus secured...